Arcus scores $305M regional development pact with Taiho; Shire, Shionogi tout PhIII ADHD study
⇨ Terry Rosen’s Arcus Biosciences has scored a $35 million development deal with Taiho in exchange for regional rights to its cancer immunotherapies. Hayward, CA-based Arcus gets the $35 million in cash spread out over three years, with another $275 million in milestones laid out for successful work. Taiho’s option for Asia is stretched out over five years.
⇨ Shire and its partner in Japan, Shionogi, say their Phase III study of Intuniv (guanfacine hydrochloride prolonged release) in adult patients with attention deficit hyperactivity disorder (ADHD) in Japan has racked up positive topline results, meeting the primary endpoint.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
